Someone might want to update that one year target price of $26. Just saying.
$CUR is a buy today $1.17. Good Luck!
Things seem to be getting overextended for CUR. Im not sure about you guys but https://activepennystocks1.blogspot.com has provided me with some pretty good trade ideas. I messed up executing some of them but thats on me.
MEGA OPP on this one ... SLNO (MC $25 M) BLOCKBUSTER in Phase 3 /Rare Disease +Orphan Status /$2+ BILLION Market /NO Debt = REAL Unknown low float stock with 1000% upside Potential and more .Next billion dollar rare disease company like SRPT here .GLTA
Soleno therapeutics (SLNO)
Market Cap $25 Million Cash: $8 Million Price $0.51
Shares Out: 47.6 Million ( 36 Million shares held by Insiders & Institutions)
•Company expects to initiate pivotal Phase III clinical trial by year-end 2017; will take approximately 9-12 months to complete
Soleno Therapeutics, Inc. (Soleno) is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The company is currently advancing its lead candidate, DCCR, a once-daily oral tablet for the treatment of PWS, into a Phase III clinical development program at the end of 2017.
Market Opportunity for PWS is Substantial.
While the lack of approved treatments for PWS alone make it difficult to assess the market, sales of Pfizer’s (NYSE: PFE) Genotrop in (somatropin) can provide some insight despite being indicate for PWS, in addition to, growth failure due to growth hormone deficiency(GHD),Turner syndrome,idiopathic short stature,and small for gestational age.This product achieved its highest revenue in 2008,with worldwide sales of approximately $900 million.While somatropin has been proven to improve growth and body composition, it does not affect the key disease component of hyperphagia and use is associated with substantial risk. Soleno is developing DCCR for the treatment of PWS,to help address the unmet need of this patient population. To assess the potential of DCCR for PWS, we performed a scenario analysis, which indicates that annual sales could be in the range of $1.1 billion given a moderate price point and 50% market penetrance.
Nice $CUR OTIC and HTBX all oversold biotech plays
Wake up long!
Anyone ever try out the-stock*dork ? I saw a post about them on the CUR board and ever since I have been hooked. .
Do you think this thing is done selling? Showing us a buy signal now on CUR? if you guys have questions you should ask awe-som*sto-cks. They often respond to my emails which is helpful.
CUR to change their stock symbol to FAIL! They feel this better reflects the path they are following!
Any idea what caused the spike in price and volume around 10 AM? Seems to be too late to be related to the article about the FDA developing guidelines about stem cell treatments and shutting down unauthorized clinics.
Complete Patent Searching Database and Patent Data Analytics Services.
Too much SPAM!
I can't wait to see this company go bankrupt!!! I'll be sooooo happy!!! Total scam and cost a lot of people a lot of money! Good riddance to them!!!
If we are to go off the RSI then you could argue that a pull back next day or so could occur on CUR before rallying up. Yo you should really check out awe-some_sto-cks, they seem on point with their stocks.
WOW !!!! CUR up to .09 cents on a pre-split basis. Great job Daly !!!!! Top notch ! TOP NOTCH !!!!
NIce to see stock's base slowly rising.
I am starting to see this stock on a lot of watch lists but have not figured out why yet. Techs/charts alone not enough for me. Researching fundamentals.
thx to Steve (I think?) for AVEO recommendation. did DD, got in at 2.35 dip, riding it to 4 in short order. that's what a good biotech looks like. anybody else in this?
"Human neural stem cell transplantation into the corpus callosum of Alzheimer's mice" wiley online 17 august 2017
Dr. Eva Feldman is still working with hk-532
It's looking like it wants to make a big move up. Willl it be a news catalyst, or a move on its own right??